Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-5.76%||11.13||0.7%||$778.03m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.72%||187.52||1.9%||$527.63m|
|GILD||Gilead Sciences, Inc.||-0.60%||66.65||1.0%||$475.82m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.79%||529.80||2.7%||$386.12m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.11%||179.83||2.0%||$331.72m|
|TXG||10X Genomics, Inc.||2.16%||201.41||0.0%||$178.72m|
|EXAS||EXACT Sciences Corp.||2.37%||130.97||18.1%||$176.05m|
|BNGO||Bionano Genomics, Inc.||1.68%||7.25||0.0%||$156.12m|
Inhibrx, Inc. is a biotechnology company. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firmâ€™s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.